mstate_nma_hr: Hazard ratios from network meta-analysis
In InnovationValueInitiative/IVI-NSCLC: The IVI-NSCLC model

Hazard ratios for first line treatments relative to gefitinib estimated using a Bayesian multi-state network meta-analyis (NMA).

1	mstate_nma_hr

A data.table with the following columns:

line: Line of treatment. Either first or second.
model: The statistical model.
tx_name: Name of the treatment.
month: Trial month.
transition: The health state transition.
mean: Mean hazard ratio from the posterior distribution.
median: Median hazard ratio from the posterior distribution.
l95: Lower limit of 95 percent credible interval from posterior distribution.
u95: Upper limit of the 95 percent credible interval from the posterior distribution.